UAB Cancer Prevention and Control Training Program (T32)

UAB癌症防治培训项目（T32）

• 批准号: 10427303
• 负责人: Ritu Aneja
• 金额: $ 44.4万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-13 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10427303
• 关键词: Cancer Control; Training Programs; cancer prevention

In 1988, the University of Alabama at Birmingham (UAB) Cancer Prevention and Control Training Program (CPCTP) was established under an R25 mechanism and has trained 154 pre- and post-doctoral fellows over the past 28 years. Located in the Deep South, an area marked by poverty and health disparities, the CPCTP provides a critical bridge for students from diverse and disadvantaged backgrounds who seek research careers in cancer prevention and control. Currently, 55% of CPCTP trainees are underserved minorities, and 65% are female. Consonant with NCI's mission to address the nation's behavioral, biomedical, and clinical research needs for a diverse workforce (PAR-16-152), we seek to transition our CPCTP to a T32 mechanism, so that we can continue to prepare a diverse pool of highly-trained scientists who have made a major career commitment to cancer prevention and control research (3 pre- & 3 post-doctoral fellows in years 1-2, and 4- pre & 4- post doctoral fellows in years 3-5, with a planned duration of 3-years for each appointment). Over 90% of graduates from our current cycle are actively engaged in research careers showing success. Our proposed T32 adds many novel components to the CPCTP, while retaining those that have been key to our success, e.g., our team science multidisciplinary approach and strong team mentorship from 32 faculty who are members of the Cancer Control and Population Sciences and Cancer Chemoprevention Programs of the UAB Comprehensive Cancer Center (CCC) - one of the nation's first 7 NCI-designated CCCs. Our efforts are supported by a solid financial commitment by the UABCCC and our proposed aims are to: 1) recruit, educate, train and evaluate pre- and postdoctoral fellows from diverse academic disciplines to conduct interdisciplinary research in cancer prevention and control; 2) recruit a diverse cadre of well-qualified trainees who include members of minority groups, (i.e., African-Americans, Latinos/ Hispanics, and other disadvantaged groups), and capitalize on UAB's networks and resources to promote research in health disparities within the framework of cancer prevention and control; 3)provide a specialized core didactic and tailored research curricula and rich learning opportunities in cancer prevention and control (e.g., seminars, grant preparation/mock reviews), that complement (not duplicate) other UAB training programs; 4) foster the development of independent research careers in cancer prevention and control through mentoring by senior faculty who have established track records in funded research; 5) further the development of all trainees via additional coursework, additional degrees (i.e., MSPH), and obtaining independent research fellowships or career awards (e.g., F31/32, K99, DP5); 6) educate our trainees in the Responsible Conduct of Research and in areas of professional development that will enhance their future successes in research careers at universities, private institutions, or within the federal government; and 7) emphasize interdisciplinary research training (team science) to enable trainees to gain competence in at least two research areas and enhance their future ability to collaborate with professionals in other areas.

1988年，亚拉巴马大学伯明翰分校（UAB）癌症预防和控制培训计划 （CPCTP）是根据R25机制建立的，已培训了154名博士前和博士后研究员， 过去的28年。CPCTP位于南部腹地，一个以贫困和健康差距为标志的地区， 为寻求研究职业的不同和弱势背景的学生提供了一个重要的桥梁 癌症预防和控制。目前，55%的CPCTP学员是服务不足的少数民族，65%是 女性与NCI致力于国家行为、生物医学和临床研究的使命相一致 （PAR-16-152），我们寻求将CPCTP过渡到T32机制，以便我们 我可以继续培养一批训练有素的科学家，他们已经做出了重大的职业承诺， 癌症预防和控制研究（1-2年3名博士前和3名博士后研究员，4名博士前和4名博士后研究员） 3-5年的博士研究员，每次任命的计划期限为3年）。超过90%的毕业生 从我们目前的周期积极从事研究事业显示成功。我们提出的T32增加了 CPCTP的许多新组件，同时保留了那些对我们成功至关重要的组件，例如，我们 团队科学的多学科方法和强大的团队导师从32名教师谁是成员的 UAB癌症控制和人口科学及癌症化学预防计划 癌症中心（CCC）-全国首批7个NCI指定的CCC之一。我们的努力得到了坚实的支持， UABCCC的财政承诺和我们提出的目标是：1）招募，教育，培训和评估 来自不同学科的博士前和博士后研究员，在癌症方面进行跨学科研究 （2）招募一批多样化的合格受训人员，包括少数民族成员; 组，（即，非洲裔美国人、拉丁美洲人/西班牙裔和其他弱势群体），并利用UAB的 在癌症预防框架内促进健康差距研究的网络和资源 3）提供专业的核心教学和量身定制的研究课程和丰富的学习机会 在癌症预防和控制中（例如，研讨会、赠款准备/模拟审查）、补充（不 重复）其他UAB培训计划; 4）促进癌症独立研究事业的发展 预防和控制，由在受资助的项目中建立了跟踪记录的高级教师进行指导。 研究; 5）通过额外的课程，额外的学位（即，MSPH）， 并获得独立的研究奖学金或职业奖（例如，F31/32、K99、DP 5）; 6）教育我们的 在负责任的研究行为和专业发展领域的学员，将提高 他们未来在大学、私立机构或联邦政府内的研究事业中取得的成功; 7）强调跨学科研究训练（团队科学），使受训者获得at 至少两个研究领域，并提高他们未来与其他领域的专业人士合作的能力。

项目成果

"Clinical trials are space travel": Factors of psychological response to recurrence among oncologists enrolling patients in treatment optimization trials.

• DOI: 10.1002/cam4.6710
• 发表时间: 2023-12
• 期刊: Cancer medicine
• 影响因子: 4

Health behaviors and well-being among those "living" with metastatic cancer in Alabama.

阿拉巴马州转移性癌症“生活者”的健康行为和幸福感。

• DOI: 10.1007/s00520-021-06583-1
• 发表时间: 2022
• 期刊: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
• 作者: Bail,JenniferR;Bail,SumanthV;Cagle,Jessica;Tiesi,Koriann;Caffey,Jayla;Bakitas,Marie;Demark-Wahnefried,Wendy
• 通讯作者: Demark-Wahnefried,Wendy

Pediatric May-Thurner Syndrome-Systematic review and individual patient data meta-analysis.

• DOI: 10.1111/jth.15284
• 发表时间: 2021-05
• 期刊: Journal of thrombosis and haemostasis : JTH
• 作者: Avila L;Cullinan N;White M;Gaballah M;Cahill AM;Warad D;Rodriguez V;Tarango C;Hoppmann A;Nelson S;Kuhn T;Biss T;Weiss A;Temple M;Amaral JG;Amiri N;Xavier AC;Renzi S;Brandão LR
• 通讯作者: Brandão LR

Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance.

克服同源重组水平和PARP抑制剂耐药性的策略。

• DOI: 10.1158/1535-7163.mct-20-0992
• 发表时间: 2021-09
• 期刊: Molecular cancer therapeutics
• 影响因子: 5.7

Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent.

• DOI: 10.1002/cam4.4095
• 发表时间: 2021-08
• 期刊: Cancer medicine
• 影响因子: 4
• 作者: Behring M;Ye Y;Elkholy A;Bajpai P;Agarwal S;Kim HG;Ojesina AI;Wiener HW;Manne U;Shrestha S;Vazquez AI
• 通讯作者: Vazquez AI